Phase 2 dose finding, 2021
A Lancet trial in 706 adults reported 6.0 to 10.8 percent weight loss on cagrilintide alone against 3.0 percent on placebo, beating liraglutide at the top dose.
SourceBack to search
Weight LossMetabolic
Cagrilintide
Cagrilintide is a long acting amylin analogue from Novo Nordisk, developed both as a standalone obesity treatment and as half of the CagriSema combination with semaglutide. It is investigational and is not approved in the United States or Europe.
- Lowest cost / mg
- $4.55/mg
- at Amino Club
- Vendors listed
- 34
- In stock
- 49 of 50
- listings
- COA reports
- 36
Vendor listings
Compare Cagrilintide prices.
Show prices as
50 listings · Cagrilintide
In stock5mgseen 6d ago
In stock5mgseen 6d ago
- Amino ClubLowest $/mg
In stock10mgseen 6d ago
In stock5mgseen 7d ago
In stock5mgseen 4d ago
In stock5mgseen 4d ago
In stock5mgseen 6d ago
In stock5mgseen 3d ago
In stock5mgseen 4d ago
In stock5mgseen 4d ago
In stock5mgseen 4d ago
In stock5mgseen 3d ago
In stock10mgseen 7d ago
In stock5mgseen 3d ago
In stock10mgseen 4d ago
In stock10mgseen 4d ago
In stock5mgseen 4d ago
In stock10mgseen 4d ago
In stock10mgseen 6d ago
In stock10mgseen 4d ago
Overview
What is Cagrilintide?
Cagrilintide is a long acting amylin analogue from Novo Nordisk, developed both as a standalone obesity treatment and as half of the CagriSema combination with semaglutide. It is investigational and is not approved in the United States or Europe.
- Weight Management
- Appetite Control
- Satiety Signalling
- Glycemic Control
What the research reports
Reported benefits of Cagrilintide
Outcomes described across the published Cagrilintide literature and ongoing study. Read each as research context, not a promised result.
- 01
Amylin mediated satiety effect
Acts on amylin receptors to influence satiety signalling, a mechanism distinct from the GLP-1 pathway used by most weight loss peptides. Reported in research settings.
- 02
Standalone weight research
A 2021 dose finding phase 2 trial reported 6.0 to 10.8 percent weight loss against 3.0 percent on placebo over 26 weeks. Reported in research settings.
- 03
Combination weight performance
As part of CagriSema, trials reported 20.4 percent weight loss against 3.0 percent placebo, exceeding either component used alone. Reported in research settings.
- 04
Blood pressure trial signal
REDEFINE 1 analysis reported systolic blood pressure down 10.9 mmHg against 2.8 mmHg on placebo in adults with overweight or obesity. Reported in research settings.
- 05
Cardiac safety assessment
A thorough QT study in 105 healthy participants found no clinically relevant QTc prolongation or arrhythmia signal at 4.5 mg. Reported in research settings.
Dosage and protocol
Cagrilintide dosage and protocol
Trial protocols escalate weekly from 0.3 mg to a 2.4 mg target, raising the dose every four weeks across a 68 week study period. Figures describe study protocols, not a personal regimen.
- Route
- Subcutaneous injection
- Example range
- 0.3-2.4 mg
- Frequency
- Once weekly
- Timing
- Once weekly on the same day, any time, with or without meals. Rotate injection sites.
Clinical evidence
Clinical evidence for Cagrilintide
The published record, labeled by strength so you can see what is settled and what is still emerging.
REDEFINE 1 combination trial
A 2025 NEJM phase 3 trial in 3,417 adults reported 20.4 percent weight loss on cagrilintide with semaglutide against 3.0 percent on placebo over 68 weeks. Reported in the cited paper.
SourceThorough QT safety study 2024
A phase 1 study in 105 healthy participants found no clinically relevant QTc prolongation or arrhythmia signal at doses up to 4.5 mg of cagrilintide. Reported in the cited paper.
SourceInteractions
How it pairs with other peptides
- Semaglutide
- The basis of CagriSema. Amylin and GLP-1 pathways are complementary rather than overlapping.
- Tirzepatide
- Not studied together. Both suppress appetite, so stacking adds gastrointestinal burden without trial support.
- Insulin therapy
- Amylin analogues slow gastric emptying, so timing against insulin needs clinical oversight.
- Pramlintide
- Both are amylin analogues, so combining duplicates the same receptor target with no added benefit.
Questions
Frequently asked questions.
What is Cagrilintide?
Cagrilintide is a peptide compound used in research settings. It is commonly studied for its role in weight loss, metabolic, and many researchers compare supplier quality, purity, and testing data before purchasing.
What are the research benefits of Cagrilintide?
Cagrilintide is often evaluated for its potential influence on signaling pathways, recovery support, and targeted research applications. Research interest varies by peptide, formulation, and study design, so buyers typically review purity, dose, and independent lab verification before choosing a source.
How does Cagrilintide work?
Like other research peptides, Cagrilintide is typically studied for how it interacts with specific biological pathways and receptor systems. In practice, the way it is formulated, dosed, and tested matters as much as the compound itself, which is why verified suppliers and transparent COAs are important.
Is Cagrilintide for research use only?
Yes, products like Cagrilintide are generally intended for research, laboratory, or educational use and are not marketed as approved human therapeutics. Always follow local laws, lab safety practices, and institutional requirements before handling or studying any peptide.
What should I look for before buying Cagrilintide?
Key checks include verified COA data, peptide form and concentration, supplier reputation, stock status, and cost per mg. Comparing pricing and testing records side-by-side helps reduce the risk of buying an under-tested or misrepresented product.
